Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
The University of Queensland
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07485010CT.gov Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mycobacterial Infectious Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ceftriaxone (this asset) | The University of Queensland | P2 | CCC · 53 |
| Thalidomide | National Center for Research Resources (NCRR) | P2 | B |
| Bacillus Calmette-Guerin Strain Tice Live Antigen | Johns Hopkins University | P2 | B |
| Clofazimine | The University of Queensland | P2 | CCC |
| Bedaquiline | The University of Queensland | P2 | CCC |
| Ansamycin | The University of Queensland | P2 | CCC |
| Linezolid | The University of Queensland | P2 | CCC |
| Ethambutol | The University of Queensland | P2 | CCC |
| Tigecycline | The University of Queensland | P2 | CCC |
+13 more in the Mycobacterial Infectious Disease cohort
Other indications for Ceftriaxone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cholangitis | — | P4 | BB · 67 |
| Cirrhosis Of Liver | — | P4 | BB · 65 |
| Amyotrophic Lateral Sclerosis | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ceftriaxone in Mycobacterial Infectious Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ceftriaxone-mycobacterial-infectious-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →